AstraZeneca may resume U.S. COVID-19 vaccine trial this week

Oct. 20, 2020

According to reports from four Reuters sources, AstraZeneca's vaccine trial in the U.S. could continue as early as this week. 

The drugmaker's large, late-stage trial has been on hold since September 6, after a participant in the company’s UK trial reportedly contracted transverse myelitis, a rare spinal inflammatory disorder.

Sources also say that the FDA is requiring trial researchers to add information about the incident to consent forms signed by participants.

Read the Reuters report